Bioavailability Enhancement: When to Use Hot-Melt Extrusion versus Spray Drying - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bioavailability Enhancement: When to Use Hot-Melt Extrusion versus Spray Drying
Enhancing bioavailability can be achieved through hot-melt extrusion or spray drying. The drug product's API properties and stage of development are important factors to consider when deciding which technique to use.


Pharmaceutical Technology
Volume 36, Issue 8, pp. 44-45

A Q&A with Bend Research

Enhancing bioavailability can be achieved through hot-melt extrusion (HME) or spray drying. The drug product's API properties and stage of development are important factors to consider when deciding which technique to use. There are also considerations to be made with regard to process, time, and cost. To gain perspective on these issues as well as insight into more recent advances in HME and spray drying, Pharmaceutical Technology spoke to Bend Research, an independent drug-formulation development and manufacturing company based in Bend, Oregon.

Choosing the right technique

PharmTech: One tool for bioavailability enhancement is to create amorphous solid dispersions through such processes as hot-melt extrusion (HME) or spray drying. What factors come into play when deciding whether to produce the amorphous solid dispersions through HME or spray drying?

Bend Research: Both spray drying and HME can be used to produce amorphous dispersions that enhance the bioavailability of poorly soluble compounds. There are a number of factors that come into play when deciding to progress an amorphous dispersion. These include performance, projected dose, stability, and manufacturability. When choosing which technology to employ for optimizing the amorphous dispersion formulation's performance, two key factors are: the physical-chemical properties of the API and the phase of development, which influences the amount of API available for formulation development.

Important physical–chemical properties include the solubility of the API in either a solvent (for spray drying) or polymer (for HME), the melting temperature of the API, and the LogP value of the API. For spray drying, the solubility of the API in the solvent is crucial to ensure a readily scalable and viable process, whereas for HME, the solubility of the API in the polymer is crucial to ensure a thermodynamically stable system. The particle size of the API, which influences the dissolution rate during processing, can also be crucial for complete dissolution into the polymer melt.

The processing temperature is important for HME because the API must either melt to form a dispersion or dissolve through high shear forces into the molten polymer. If the processing temperature is too high, the compound or the polymer used in the formulation can degrade. Typically, 200 C to 225 C is regarded as the upper processing-temperature limit for an effective HME process. Although compounds can be extruded at higher processing temperatures, this physical situation often produces a partially crystalline formulation instead of an amorphous dispersion.

The phase of development is also an important factor in process selection. For example, for early-stage or discovery-support activities, API availability is often limited. This limited API availability tends to make spray drying the preferable process because its feasibility can be determined with as little as 50 to 100 mg of API, whereas several grams of API are typically required to develop an initial HME process. For APIs that are amenable to HME, typically after proof-of-concept clinical studies, when hundreds of grams of API are available, an initial spray-drying process can be converted from spray drying to HME.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here